Tokyo, Japan

Fumihito Ushiyama

USPTO Granted Patents = 8 

 

 

Average Co-Inventor Count = 9.3

ph-index = 3

Forward Citations = 16(Granted Patents)


Location History:

  • Toshima-ku, JP (2013 - 2015)
  • Tokyo, JP (2012 - 2016)

Company Filing History:


Years Active: 2012-2016

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Fumihito Ushiyama: Innovator in Pharmaceutical Compounds

Introduction

Fumihito Ushiyama is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with therapeutic applications. With a total of 8 patents, Ushiyama's work has garnered attention for its innovative approaches to drug development.

Latest Patents

Ushiyama's latest patents include a partially saturated nitrogen-containing heterocyclic compound. This compound exhibits a superior PHD2 inhibitory effect and is represented by a specific general formula. Additionally, he has developed an azole derivative, which consists of novel compounds that bind to FKBP12. These compounds are aimed at providing new therapeutics for the prevention or treatment of alopecia.

Career Highlights

Throughout his career, Ushiyama has worked with prominent companies in the pharmaceutical industry, including Taisho Pharmaceutical Co., Ltd. and Toyama Chemical Co., Ltd. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research.

Collaborations

Ushiyama has collaborated with esteemed colleagues such as Taro Kiyoto and Yasuhiro Tsutsui. These partnerships have facilitated the exchange of ideas and fostered innovation in their respective fields.

Conclusion

Fumihito Ushiyama's contributions to pharmaceutical innovations highlight his role as a leading inventor in the industry. His patents reflect a commitment to advancing therapeutic solutions, making a significant impact on healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…